Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study
-
- Carlo Visco
- Division of Hematology, San Bortolo Hospital, Vicenza, Italy;
-
- Francesco Rodeghiero
- Division of Hematology, San Bortolo Hospital, Vicenza, Italy;
-
- Alessandra Romano
- Hematology, University Hospital, Catania, Italy;
-
- Federica Valeri
- Hematology and Oncology, Città della Salute e della Scienza, Torino, Italy;
-
- Michele Merli
- Department of Medicine and Surgery, University of Insubria, Varese, Italy;
-
- Giulia Quaresimini
- Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy;
-
- Stefano Volpetti
- Hematology and Bone Marrow Transplant Unit, University Hospital, Udine, Italy;
-
- Roberto M. Santi
- Hematology, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy;
-
- Giuseppe Carli
- Division of Hematology, San Bortolo Hospital, Vicenza, Italy;
-
- Elisa Lucchini
- Hematology and Bone Marrow Transplant Unit, University Hospital, Udine, Italy;
-
- Francesco Passamonti
- Department of Medicine and Surgery, University of Insubria, Varese, Italy;
-
- Alessandro Rambaldi
- Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy;
-
- Giovanna Motta
- Hematology, University Hospital, Catania, Italy;
-
- Alessandra Borchiellini
- Hematology and Oncology, Città della Salute e della Scienza, Torino, Italy;
-
- Emanuele S. G. d’Amore
- Institute of Pathology, San Bortolo Hospital, Vicenza, Italy
-
- Marco Ruggeri
- Division of Hematology, San Bortolo Hospital, Vicenza, Italy;
抄録
<jats:p>Visco and colleagues report excellent response to eltrombopag in immune thrombocytopenia in the setting of chronic lymphoproliferative disease.</jats:p>
収録刊行物
-
- Blood
-
Blood 134 (20), 1708-1711, 2019-09-30
American Society of Hematology